What is Celcuity LLC?
, a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.61B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 23,100,000 shares $317.8M | 0 |
| 6-9months | 937,000 shares $5.1M | 0 |
| 9-12months | 424,100 shares $2.8M | 0 |